HC Wainwright Analysts Decrease Earnings Estimates for Cibus

Cibus, Inc. (NASDAQ:CBUS) – Equities researchers at HC Wainwright reduced their Q4 2024 earnings per share estimates for Cibus in a note issued to investors on Monday, November 11th. HC Wainwright analyst A. Dayal now anticipates that the company will earn ($1.00) per share for the quarter, down from their previous forecast of ($0.96). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cibus’ current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Cibus’ FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

A number of other equities analysts have also weighed in on the stock. Alliance Global Partners cut their price objective on shares of Cibus from $25.00 to $23.50 and set a “buy” rating for the company in a research report on Tuesday, September 24th. Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a report on Friday, July 19th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of Cibus in a report on Tuesday, October 22nd.

Cibus Trading Down 7.7 %

Shares of CBUS stock opened at $4.90 on Wednesday. The company has a market capitalization of $129.65 million, a price-to-earnings ratio of -0.22 and a beta of 1.79. The firm has a 50-day moving average price of $4.05 and a 200 day moving average price of $8.60. Cibus has a twelve month low of $2.86 and a twelve month high of $23.18.

Institutional Investors Weigh In On Cibus

A number of institutional investors have recently bought and sold shares of CBUS. FMR LLC raised its holdings in shares of Cibus by 16.9% in the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock worth $12,757,000 after purchasing an additional 566,328 shares during the period. Vanguard Group Inc. lifted its position in Cibus by 3.7% during the first quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock valued at $16,215,000 after buying an additional 26,017 shares in the last quarter. Armistice Capital LLC purchased a new stake in Cibus during the second quarter worth approximately $5,083,000. Bank of New York Mellon Corp acquired a new stake in shares of Cibus in the second quarter worth $529,000. Finally, Old West Investment Management LLC raised its stake in shares of Cibus by 3.6% in the 2nd quarter. Old West Investment Management LLC now owns 53,247 shares of the company’s stock valued at $524,000 after acquiring an additional 1,868 shares during the period. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.